Methods to Engage Patients in the Modern Clinic

CONCLUSION: These technological advances provide distinct advantages to the provider and patient, but also have a burden of time for evaluation of the data for the provider and disparate access to certain technologies for patients. The development of these technologies has been fast-tracked since the start of the Covid-19 pandemic. With the explosion in telehealth and medical device development, advancement of medical technology is not showing any signs of slowing down. It is paving a new way to interact with patients in the future.PMID:34813954 | DOI:10.1016/j.anai.2021.11.013
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

AbstractPurpose of ReviewPrior to the SARS-CoV-2 novel coronavirus (COVID-19) pandemic, access and utilization of telemedicine in the USA was negligeable, with very little interest from both the public and healthcare sectors. Since that time, telemedicine technology and services have undergone explosive growth and investment and are poised to change the way healthcare is delivered now and in the future. But has telemedicine truly changed the way healthcare is delivered or is it merely a temporary fix for a temporary pandemic?Recent FindingsThis global public health emergency has exposed vulnerabilities in our healthcare sy...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Expert Rev Respir Med. 2022 Jan 17. doi: 10.1080/17476348.2022.2027758. Online ahead of print.ABSTRACTINTRODUCTION: With the abrupt establishment of the COVID-19 pandemic, treatment for immunological diseases may be influenced by the SARS-CoV-2 infection, including asthma and other allergies. Immunobiologics play a pivotal role in the management of severe symptoms of allergy and an opinion regarding the continuity of this treatment during the COVID-19 pandemic must be issued.AREAS COVERED: In Brazil and other countries, patients with severe asthma were included in the priority groups for COVID-19 vaccination, even those wh...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
Ann Allergy Asthma Immunol. 2021 Dec 28:S1081-1206(21)01310-7. doi: 10.1016/j.anai.2021.12.013. Online ahead of print.ABSTRACTOBJECTIVE: To summarize the current literature of the psychological impacts of coronavirus disease 2019 (COVID-19) on people with allergic diseases and to identify gaps in need of future research.DATA SOURCES: Ovid MEDLINE(R) and Embase Classics + Embase from 1947 to present (October 18, 2021) were searched using a search strategy that included the following keywords: allergic diseases, covid*, and psychological disorders.STUDY SELECTIONS: Primary manuscripts and abstracts using online and telephone...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Allergol Immunopathol (Madr). 2022 Jan 1;50(1):99-103. doi: 10.15586/aei.v50i1.492. eCollection 2022.ABSTRACTBACKGROUND: The novel disease caused by the new coronavirus SARS-CoV-2 has caused an unprecedented global pandemic. Care providers of asthmatic children are increasingly con-cerned; as viral infections are one of the primary triggers of asthma flare-up. However, the effect of SARS-CoV-2 as well as the generated worldwide lockdown on asthmatic children is unknown.OBJECTIVE: The aim of this study was to analyze the effects of pandemic SARS-CoV-2 in pediat-ric asthma control.MATERIAL AND METHODS: A retrospective, open,...
Source: Allergologia et Immunopathologia - Category: Allergy & Immunology Authors: Source Type: research
Conclusion: The overall knowledge and awareness of pediatricians and, especially, family physicians regarding the management of pediatric asthma/allergic rhinitis during the pandemic is not at a satisfactory level. There is an urgent need to inform them about updated recommendations appearing in recent guidelines published by allergy organizations.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Coronavirus disease of 2019 (COVID-19) is a respiratory illness characterized by fever, cough, dyspnea, fatigue, and lymphopenia. Severe COVID-19 complications can manifest as viral pneumonia and may lead to severe acute respiratory syndrome and, in some cases, death [1, 2]. As of December 2021, SARS-CoV-2 has caused more than 263,300,000 infections, and over 5,221,000 deaths. Since December 2020, over 8,033,000,000 vaccine doses have been administered [3]. A global systematic review conducted during the COVID-19 pandemic of the general public's psychological outcomes found relatively high rates of anxiety (6.33% to 50.9%)...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Review Source Type: research
Our understanding of risk factors and interventions influencing outcomes from COVID-19 has continued to evolve, revealing advances emerging from hypotheses formed at the start of the pandemic. Epidemiologic studies have shown that asthma control, rather than a diagnosis of asthma, is a determinant of COVID-19 severity. Clinical outcomes in patients with primary immunodeficiencies, even in those with impaired cellular immunity, are variable. IL-6 has emerged as a reliable biomarker of COVID-19 severity and large clinical trials have shown the potential for improving outcomes through inhibition of IL-6 signaling in some patients.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Ann Allergy Asthma Immunol. 2021 Dec 16:S1081-1206(21)01308-9. doi: 10.1016/j.anai.2021.12.012. Online ahead of print.NO ABSTRACTPMID:34923126 | DOI:10.1016/j.anai.2021.12.012
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
As the world faces the coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have been raised that asthma patients could be at increased risk of SARS-CoV-2 infection and disease severity. However, it appears that asthma is not an independent risk factor for both. Furthermore, asthma is not over-represented in hospitalised patients with severe pneumonia due to SARS-CoV-2 infection and there was no increased risk of asthma exacerbations triggered by SARS-CoV-2. There is accumulating evidence that asthma phenotypes and comorbidities are important f...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Respiratory clinical practice, Asthma and allergy COVID-19 Reviews Source Type: research
The coronavirus disease 2019 (COVID-19) pandemic profoundly altered the way that society functioned, with resultant shifts in behavior and exposures particularly when the orders for national shelter in place were implemented in mid-March 2020. These changes may have substantially impacted patients with chronic diseases including asthma, which disproportionately affects underserved minority children.1 In addition to changes in exposures such as viruses and environmental triggers, changes in health care access and utilization impact asthma morbidity.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | COVID-19 | Medical Devices | Pandemics | Study | Websites